<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00820014</url>
  </required_header>
  <id_info>
    <org_study_id>ESBA105CRD03</org_study_id>
    <nct_id>NCT00820014</nct_id>
  </id_info>
  <brief_title>Ocular Biodistribution Study for Topically Applied ESBA105</brief_title>
  <official_title>Evaluation of Tolerability, Safety and Ocular Pharmacokinetics of Topically Applied ESBA105 in Patients Undergoing Cataract Surgery or Combined Cataract Surgery and Vitrectomy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>ESBATech AG</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>ESBATech AG</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine whether ESBA105, a single-chain (scFv) antibody&#xD;
      against TNF-alpha, efficiently penetrates into the anterior chamber and the vitreous body&#xD;
      upon topical administration to the eye.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      ESBA105 is a topically administered tumour necrosis factor alpha (TNF-alpha) inhibitor that&#xD;
      has significant therapeutic potential in various inflammatory intraocular diseases. In animal&#xD;
      experiments, ESBA105 was shown to efficiently penetrate into the inner of the eye upon&#xD;
      topical administration, associated with very low systemic exposure. A recently completed&#xD;
      Phase I trial with topical ESBA105 has confirmed the safety of topical administration to the&#xD;
      human eye and the low systemic exposure using this route of administration.&#xD;
&#xD;
      This study is designed to determine the intraocular levels and the specific intraocular&#xD;
      distribution pattern of ESBA105 following topical administration to the human eye. In&#xD;
      addition it shall be explored whether topical administration of ESBA105 reduces intraocular&#xD;
      inflammation following cataract surgery.&#xD;
&#xD;
      Three different dose regimens will be applied to four different patient cohorts. Three&#xD;
      patient cohorts will be conducted in an open label design and one in a double-masked, placebo&#xD;
      controlled design.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>January 2009</start_date>
  <completion_date type="Actual">September 2010</completion_date>
  <primary_completion_date type="Actual">September 2010</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Determination of intraocular ESBA105 levels, local biodistribution (aqueous and vitreous humor) and intraocular pharmacokinetics upon topical administration.</measure>
    <time_frame>Collection of respective biological matrices at occasion of ocular surgery</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Exploratory assessment of the anti-inflammatory potential of prophylactic, topical ESBA105 for prevention of post-surgical inflammation following cataract surgery.</measure>
    <time_frame>10 Days following ocular surgery</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Assessment of local tolerability and safety of topical ESBA105.</measure>
    <time_frame>up to 10 Days following ocular surgery</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Assessment of systemic exposure upon topical application of ESBA105.</measure>
    <time_frame>1 Day following ocular surgery</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">79</enrollment>
  <condition>Cataract</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>ESBA105 eye drops</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo control (vehicle)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo control (vehicle) eye drops applied 4-times a day for 4 days before ocular surgery</description>
    <arm_group_label>1</arm_group_label>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Male or female Caucasian patients â‰¥18 years.&#xD;
&#xD;
          -  Written informed consent prior to any study procedures including screening tests for&#xD;
             eligibility.&#xD;
&#xD;
          -  Patients should be in good health as determined by past medical history, physical&#xD;
             examination, vital signs, electrocardiogram (ECG), and laboratory tests at screening.&#xD;
&#xD;
          -  Ability to administer eye drops (personally or administered by another person).&#xD;
&#xD;
        Cataract patients:&#xD;
&#xD;
          -  Eligible for routine, uncomplicated senile cataract surgery.&#xD;
&#xD;
        Vitrectomy patients:&#xD;
&#xD;
          -  Diagnosis of epiretinal fibroplasia requiring vitrectomy and cataract surgery.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Treated glaucoma / elevated intraocular pressure (IOP) requiring therapy.&#xD;
&#xD;
          -  History of chronic or recurrent intraocular inflammatory disease.&#xD;
&#xD;
          -  Uncontrolled diabetes mellitus (fasting blood glucose &gt;15 mmol/L).&#xD;
&#xD;
          -  Diabetic retinopathy with history of laser photocoagulation.&#xD;
&#xD;
          -  Patients with a single eye or a pinholed visual acuity (VA) 20/200 or worse measured&#xD;
             on Snellen chart in the non-study eye.&#xD;
&#xD;
          -  Iris atrophy in the eye to undergo surgery.&#xD;
&#xD;
          -  Pregnant or breast-feeding women or women of childbearing potential, who with their&#xD;
             partners refuse to use 2 reliable methods of contraception&#xD;
&#xD;
          -  History of collagenosis or systemic vasculitis.&#xD;
&#xD;
          -  Patients who have had ocular surgery (including laser surgery) in the study eye within&#xD;
             3 months or in the contralateral eye within 2 weeks prior to screening.&#xD;
&#xD;
          -  Patients who have an active systemic or local (anywhere in the body) bacterial and/or&#xD;
             viral infection.&#xD;
&#xD;
          -  Positive or unclear QuantiFERON-TB Gold assay result.&#xD;
&#xD;
          -  Participation in a clinical study with investigational drugs within 3 months prior to&#xD;
             screening.&#xD;
&#xD;
          -  Inability to comply with the study requirements.&#xD;
&#xD;
          -  Patients with known, severely impaired hepatic function, or laboratory values&#xD;
             reflecting inadequate hepatic function.&#xD;
&#xD;
          -  Patients with pre-existing chronic renal failure defined by a calculated creatinine&#xD;
             clearance (CrCl) of &lt; 40 mL/min, using the Cockcroft-Gault estimate for glomerular&#xD;
             filtration rate&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Michael A Thiel, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Kantonsspital Luzern, Augenklinik, CH-6000 Luzern 16, Switzerland</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Pallas Gruppe</name>
      <address>
        <city>Olten</city>
        <state>Solothurn</state>
        <zip>4600</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kantonsspital Luzern, Augenklinik, CH-6000 Luzern 16, Switzerland</name>
      <address>
        <city>Luzern</city>
        <zip>6000</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Switzerland</country>
  </location_countries>
  <verification_date>January 2009</verification_date>
  <study_first_submitted>January 8, 2009</study_first_submitted>
  <study_first_submitted_qc>January 8, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 9, 2009</study_first_posted>
  <last_update_submitted>September 23, 2010</last_update_submitted>
  <last_update_submitted_qc>September 23, 2010</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 24, 2010</last_update_posted>
  <responsible_party>
    <name_title>Peter Lichtlen, Medical Director</name_title>
    <organization>ESBATech AG</organization>
  </responsible_party>
  <keyword>ESBA105</keyword>
  <keyword>scFv antibody fragment</keyword>
  <keyword>cataract surgery</keyword>
  <keyword>pharmacokinetics</keyword>
  <keyword>biodistribution</keyword>
  <keyword>Irvine-Gass syndrome</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cataract</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

